Clinical Trial Update: Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial of DE-108 Ophthalmic Solution in patients scheduled for cataract surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• DE-108 Ophthalmic Solution

Snippet

Sponsor: Santen Pharmaceutical Co., Ltd. | Conditions: Cataract Surgery | Phase 3 | Status: COMPLETED